Once integration is completed, the partners plan to accelerate commercial rollout across India, anticipated in 2026.

CHICAGO--(BUSINESS WIRE)-- Cardio Diagnostics Holdings Inc (Nasdaq: CDIO), an artificial intelligence-powered precision cardiovascular medicine company, today announced the launch of PrecisionCHD™, an ...

A lot of longevity is fascinating, but you could listen to 10 different podcasts about it and find different, conflicting ...

One of the strongest predictors of long-term mortality among patients undergoing a cardiac stress test is the need for a pharmacologic versus treadmill test, new data show. Moreover, although the risk ...

Cardio Diagnostics Holdings Inc. (NASDAQ:CDIO), an AI-powered precision cardiovascular medicine company, is making progress in gaining broad access to Medicare reimbursement for its Epi+Gen CHD™ and ...

CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics, Inc, a biotechnology company making cardiovascular disease prevention and early detection more accessible, personalized and precise, announces the launch ...

Cardio Diagnostics Holdings will partner with a longtime distribution leader in India and an Indian network of nearly 300 ...

The final gapfill payment rate for both the Epi+Gen CHD™ and PrecisionCHD™ tests is higher at $854 compared to the preliminary gapfill payment rates of $350 for Epi+Gen CHD™ and $684.76 for ...

Yes, in the sense that it meets the minimum guidelines. It is moderate intensity exercise and it counts toward your minutes per week (no matter what your heart rate is while you do it).

Plenty of research touts the importance of cardiorespiratory fitness (CRF)—also known as cardio fitness, cardiovascular endurance, and aerobic fitness—as a health marker, as well as an athletic ...